Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Clinical Trial ID NCT01275677

PubWeight™ 16.49^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01275677

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.	Oncologist	2013	2.55
2	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.	Arch Pathol Lab Med	2013	2.54
3	Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.	J Natl Cancer Inst	2013	2.28
4	Strategies for modern biomarker and drug development in oncology.	J Hematol Oncol	2014	1.89
5	Luminal breast cancer: from biology to treatment.	Nat Rev Clin Oncol	2013	1.16
6	Treatment of HER2-positive breast cancer.	Breast	2013	1.09
7	HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer.	Breast Cancer Res	2013	1.04
8	Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.	Clin Cancer Res	2012	1.01
9	The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.	Mol Oncol	2015	1.01
10	Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.	Oncologist	2014	0.89
11	Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers.	Cell Rep	2013	0.85
12	Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term.	Breast Cancer Res	2012	0.75